A Phase II Single Arm Study of VELCADE [bortezomib] and DOXIL (PLD [pegylated liposomal doxorubicin] [doxorubicin liposomal]) in Patients With Relapsed Multiple Myeloma Previously Treated With VELCADE

Trial Profile

A Phase II Single Arm Study of VELCADE [bortezomib] and DOXIL (PLD [pegylated liposomal doxorubicin] [doxorubicin liposomal]) in Patients With Relapsed Multiple Myeloma Previously Treated With VELCADE

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Oct 2008 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Sep 2008 Actual initiation date added as 1 Jun 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top